Monotherapie mit Clodronat bei tumorinduzierter Hypercalcämie

Autor:	D. Fritze, H. Harjung
Rok vydání:	2008
Předmět:	Leiomyosarcoma medicine.medical_specialty Hypercalcaemia business.industry Standard treatment Uterus Phases of clinical research General Medicine medicine.disease Gastroenterology medicine.anatomical_structure Breast cancer Bronchial carcinoma Calcitonin Internal medicine medicine business
Zdroj:	DMW - Deutsche Medizinische Wochenschrift. 115:48-52
ISSN:	1439-4413 0012-0472
DOI:	10.1055/s-2008-1064969
Popis:	In the course of a phase II study 15 patients (nine women and six men; mean age 58 [45-69] years) received 300 mg clodronate daily during a total of 16 episodes of tumour-induced hypercalcaemia. Four women had breast cancer, four patients had plasmocytoma and four had bronchial carcinoma. One woman each had leiomyosarcoma or squamous cell carcinoma of the uterus or pancreatic carcinoma, respectively. No other calcium-lowering treatment, such as forced diuresis, glucocorticoids, calcitonin or mithramycin, was employed. As early as two days after onset of treatment the serum calcium concentration fell significantly from 3.63 +/- 0.42 to 2.80 +/- 0.40 mmol/l. After a mean interval of 4.3 days the hypercalcaemia had been eliminated during 15 of the 16 episodes. The treatment was not adequate in one patient with paraneoplastic hypercalcaemia. The results indicate that this medication is to be recommended as a standard treatment of tumour-induced hypercalcaemia; side effects are minimal.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6a3ab4518f6d48f956e7e7f8522e6104 https://doi.org/10.1055/s-2008-1064969 Zobrazit plný text záznamu